Dr. Tony Holohan:

Yes, I did. In principle, we do not have any difficulty with the idea of sectors studying the potential value of antigen testing or anything else in their own sectors. We have been neither a break on that nor advising against that. In fact, our position has been one of - as with any other thing - wanting the use of these tests to be supported by well-constructed and designed validation studies. Some sectors have already come forward with that.-----